Benign Prostatic Hyperplasia-Related False-Positive of Prostate-Specific Membrane Antigen-Positron Emission Tomography in the Diagnosis of Prostate Cancer: The Achilles' Heel of Biopsy-Free Radical Prostatectomy?
- PMID: 37647549
- DOI: 10.1097/JU.0000000000003680
Benign Prostatic Hyperplasia-Related False-Positive of Prostate-Specific Membrane Antigen-Positron Emission Tomography in the Diagnosis of Prostate Cancer: The Achilles' Heel of Biopsy-Free Radical Prostatectomy?
Abstract
Purpose: Radical prostatectomy is one of the primary treatments for localized clinically significant prostate cancer. Generally, its application is based on prior biopsy. PSMA (prostate-specific membrane antigen)-PET (positron emission tomography) is considered promising in biopsy-free radical prostatectomy. The expression of PSMA in benign prostatic hyperplasia tissue and corresponding positive reaction are crucial concerns for a no-biopsy strategy. Currently, no study has explored the benign prostatic hyperplasia-related false-positive of PSMA-PET in the detection of prostate cancer. Furthermore, the influence of maximum standardized uptake value and Prostate Imaging Reporting & Data System on biopsy-free radical prostatectomy is also poorly characterized.
Materials and methods: A retrospective study was conducted on patients who received PSMA-PET because of clinical suspicion of prostate cancer and were confirmed to have benign prostatic hyperplasia or prostate cancer. The receiver operating characteristic curve was generated for maximum standardized uptake value. Results of interest were the false-positive rate of PSMA-PET and the efficacy of maximum standardized uptake value or multiparametric MRI in excluding false-positives.
Results: The benign prostatic hyperplasia-related false-positive rate of PSMA-PET in detecting prostate cancer was 30%. Maximum standardized uptake value could effectively exclude benign prostatic hyperplasia and Grade Group 1 patients with an area under the curve of 0.86; the optimal maximum standardized uptake value cutoff value with 100% specificity was 15, with a sensitivity of 41%. Notably, the sensitivity and specificity of stringent PET score and Prostate Imaging Reporting & Data System criteria (both ≥4) in diagnosing clinically significant prostate cancer were 49% and 100%, respectively.
Conclusions: Our findings revealed benign prostatic hyperplasia-related false-positive rate of PSMA-PET and provided a preliminary reference in biopsy-free radical prostatectomy.
Keywords: biopsy; false positive reactions; positron emission tomography computed tomography; prostatectomy; prostatic neoplasms.
Comment in
-
Editorial Comment.J Urol. 2023 Dec;210(6):853-854. doi: 10.1097/JU.0000000000003680.01. Epub 2023 Oct 5. J Urol. 2023. PMID: 37795816 No abstract available.
-
Editorial Comment.J Urol. 2023 Dec;210(6):854. doi: 10.1097/JU.0000000000003680.02. Epub 2023 Oct 5. J Urol. 2023. PMID: 37795824 No abstract available.
-
Biopsy-free radical prostatectomy for prostate cancer-modern reality or pipe dream?Transl Androl Urol. 2025 May 30;14(5):1165-1168. doi: 10.21037/tau-2025-8. Epub 2025 May 27. Transl Androl Urol. 2025. PMID: 40529023 Free PMC article. No abstract available.
Similar articles
-
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.Eur Urol Oncol. 2024 Apr;7(2):231-240. doi: 10.1016/j.euo.2023.08.010. Epub 2023 Sep 9. Eur Urol Oncol. 2024. PMID: 37689506
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.BJU Int. 2019 Nov;124 Suppl 1:42-49. doi: 10.1111/bju.14794. Epub 2019 Jul 9. BJU Int. 2019. PMID: 31287613
-
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.BJU Int. 2020 Feb;125(2):206-214. doi: 10.1111/bju.14944. Epub 2019 Nov 29. BJU Int. 2020. PMID: 31680398 Free PMC article. Review.
-
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806
Cited by
-
Pathological and radiological features of false-positive lesions on [68Ga]Ga-PSMA-11 PET/CT in primary staging of prostate cancer: a radio-pathology matching analysis.Eur J Nucl Med Mol Imaging. 2025 Jul;52(8):2804-2813. doi: 10.1007/s00259-025-07148-8. Epub 2025 Feb 17. Eur J Nucl Med Mol Imaging. 2025. PMID: 39960655
-
Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions - an EAU-YAU study enhancing prostate cancer detection.Prostate Cancer Prostatic Dis. 2025 Jun;28(2):435-443. doi: 10.1038/s41391-024-00904-1. Epub 2024 Nov 5. Prostate Cancer Prostatic Dis. 2025. PMID: 39501078
-
Biopsy-free radical prostatectomy: a narrative review considering rationale, limitations, and current data.Prostate Int. 2025 Jun;13(2):67-73. doi: 10.1016/j.prnil.2025.03.003. Epub 2025 Mar 18. Prostate Int. 2025. PMID: 40620872 Free PMC article. Review.
-
Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI.Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):913-924. doi: 10.1007/s00259-024-06949-7. Epub 2024 Oct 15. Eur J Nucl Med Mol Imaging. 2025. PMID: 39404788
-
Radical prostatectomy without prostate biopsy based on a noninvasive diagnostic strategy: a prospective single-center study.Prostate Cancer Prostatic Dis. 2025 Jun;28(2):496-502. doi: 10.1038/s41391-024-00931-y. Epub 2024 Dec 18. Prostate Cancer Prostatic Dis. 2025. PMID: 39695194
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous